Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma
Endocrine-Related Cancer · 2023
DOI: 10.1530/erc-22-0372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2023. Verfasst von Alessandra Mangone und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Adrenal Cortex Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Treatment for advanced adrenocortical carcinoma (ACC) consists of mitotane alone or combined with etoposide, doxorubicin, and cisplatin (EDP). Although both therapies are widely used, markers of response are still lacking. Since inflammation-based scores have been proposed as prognostic factors in ACC, we aimed to investigate their role in predicting the response to first-line chemotherapy. We performed a retrospective analysis of patients with advanced ACC treated with mitotane monotherapy or EDP ± mitotane. Clinical parameters (tumour stage at diagnosis, resection status, Ki67, time from diagnosis to treatment start, performance status, plasma mitotane levels, time in mitotane target ≥ 80%, clinically overt cortisol hypersecretion), and pretreatment inflammation-based scores (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio, derived neutrophil-to-lymphocyte ratio) were investigated. The primary endpoints were overall survival (OS) and time-to-progression (TTP) from treatment initiation, the secondary endpoint was the best objective response to treatment. We included 90 patients (59% = women, median age = 51 years) treated with mitotane monotherapy ( n = 40) or EDP ± mitotane ( n = 50). In the mitotane monotherapy cohort, NLR ≥ 5 and PLR ≥ 190 predicted shorter OS (hazard ratio (HR): 145.83, 95% CI: 1.87–11,323.83; HR: 165.50, 95% CI: 1.76–15,538.04, respectively), remaining significant at multivariable analysis including clinical variables. NLR was also associated with shorter TTP (HR: 2.58, 95% CI: 1.28–5.20), but only at univariable analysis. Patients with NLR ≥ 5 showed a worse treatment response than those with NLR < 5 ( P = 0.040). In the EDP ± mitotane cohort, NLR ≥ 5 predicted shorter OS (HR: 2.52, 95% CI: 1.30–4.88) and TTP (HR: 1.95, 95% CI: 1.04–3.66) at univariable analysis. In conclusion, inflammation-based scores, calculated from routinely measured parameters, may help predict response to chemotherapy in advanced ACC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
- Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
- Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany.
- Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK.
- Department of Endocrinology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
- Oncology Department, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
ORCID-Profile: Alessandra Mangone, Yasir S Elhassan, Cristina L Ronchi
Zitieren
APA
Mangone, A., Altieri, B., Detomas, M., Prete, A., Abbas, H., Asia, M., Elhassan, Y. S., Mantovani, G., & Ronchi, C. L. (2023). Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma. Endocrine-Related Cancer. https://doi.org/10.1530/erc-22-0372
Vancouver
Mangone A, Altieri B, Detomas M, Prete A, Abbas H, Asia M, et al. Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma. Endocrine-Related Cancer. 2023. doi:10.1530/erc-22-0372
BibTeX
@article{Mangone2023,
author = {Mangone, Alessandra and Altieri, Barbara and Detomas, Mario and Prete, Alessandro and Abbas, Haider and Asia, Miriam and Elhassan, Yasir S and Mantovani, Giovanna and Ronchi, Cristina L},
title = {Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma},
journal = {Endocrine-Related Cancer},
year = {2023},
doi = {10.1530/erc-22-0372}
}
EUVIMED